



PRECISION

AIRQ® EHR Tip Sheet

Instructions to create the Asthma Impairment and Risk Questionnaire (AIRQ®)

as a Flowsheet in the Epic electronic
health record (EHR) system

Table of Contents

Overview, Instructions, and Limitations	3
About the AIRQ®	4
AIRQ® Information for Health Care Providers	5
Printable Version of the AIRQ® in English	6
Printable Version of the AIRQ® in Spanish	7
Epic Build Guide	8
English version	8
Spanish version	12
Implementing the Follow-Up AIRQ®	16

Overview, Instructions, and Limitations

These instructions are created specifically and can be used only to create the AIRQ® and Follow-Up AIRQ® in the Epic EHR system and will not work for other conditions, treatments, therapeutic areas, or other EHR systems.

The process outlined in this resource is variable, and not all steps will apply to every health system. Any steps or settings that are not part of a health system's standard process should be excluded or modified accordingly. Any questions should be directed to the appropriate service provider. If you have any questions regarding the rights and appropriate use of the AIRQ® in the EHR, reach out to your licensing representative at RWS via email at astrazeneca@rws.com to obtain a free* license to use the AIRQ® in your clinic, practice or health care system. The practice is solely responsible for the implementing, testing, monitoring, and ongoing operation of any EHR tools.

When initiating the licensing process, be sure to include the best contacts on your team and the purpose for which you will be using the tool (eg, "patient asthma management" or "clinical trial").

The steps below describe how to integrate the AIRQ® into the EHR. The instructions are not intended to replace your health system's processes or protocols, nor do they represent an endorsement or recommendation. All decisions related to patient care should result from shared treatment decisions between health care practitioners and patients. Health care practitioners are encouraged to align shared treatment discussions with established asthma guidelines, a summary of which can be found in the [Asthma Checklist](#).

To integrate the AIRQ®, follow these 3 steps:

1. Secure licensing from RWS
2. Create the English and Spanish versions of the AIRQ® and Follow-Up AIRQ®
3. Release to the production environment and provide training on the EHR update to end users

*Licenses for use of the US English and US Spanish versions of the AIRQ® with patients in a clinic, practice, or health care system setting **are free in perpetuity**. Use of US English and US Spanish AIRQ® in **most** purely academic studies are **also free in perpetuity**. The AIRQ® is also available in a variety of other languages from RWS for free. Please contact them at astrazeneca@rws.com for details. Any language translations not currently available will require a translation fee payable to RWS. We request that you do not translate the AIRQ® yourself. Use of the AIRQ® in a clinical study sponsored by a competitor of AstraZeneca will require a licensing fee. Please contact RWS as outlined above for details.

About the AIRQ®

The AIRQ® can be found at <https://www.airqscore.com>. A [PDF](#) and [digital version](#) of the AIRQ®, as well as the [intended use document](#), are available for download and may be useful while creating the AIRQ® in Epic.

There are 2 versions of the AIRQ® available for implementation:

- **AIRQ®**: Taken by the patient at each annual visit
- **Follow-Up AIRQ®**: Taken by the patient for an HCP encounter occurring between annual visits

The instructions in this build guide are written specifically for implementing the AIRQ®. Guidance around adapting these instructions for implementing the Follow-Up AIRQ® are found toward the end of this document.


The questionnaire includes 2 key sections and a simple scoring mechanism as follows:

SECTION 1: The questions

- Each question is individually scored and equally weighted (Yes equals 1 point, No equals 0 points)

SECTION 2: The results

- The number of YES answers determines the AIRQ® Score
- The interpretation of the AIRQ® Score:



When implementing the AIRQ® flowsheet, consider adding the flowsheet to a navigator section and making a synopsis of the results available to evaluate a patient's AIRQ® Score over time.

AIRQ® Information for Health Care Providers

AIRQ® Indications

The AIRQ® is a patient assessment tool intended to help identify patients 12 years of age and older whose health may be at risk because of uncontrolled asthma. This assessment is based on a series of patient-facing questions about asthma medications, respiratory symptoms, and utilization of health care resources. Depending on the patient's responses to these questions, the patient will receive a score reflecting their level of asthma control. After completion of the AIRQ®, the patient and health care provider should discuss the responses to each of the individual questions, the total AIRQ® Score, and the patient's level of asthma control and form a treatment plan.

The AIRQ® is not intended to:

- Diagnose asthma
- Replace the advice or treatment of a health care provider
- Direct specific actions to treat, mitigate, or improve asthma
- Collect or store any laboratory values or lung function test values

Health Care Provider Instructions for Use

1. Provide your patient with the AIRQ® during or immediately prior to their appointment
2. Examine the responses to each of the individual questions, the total AIRQ® Score, and the patient's level of asthma control
3. Discuss responses to each of the individual questions, the total AIRQ® Score, and the patient's level of asthma control with your patient
4. Determine a treatment plan with your patient based on the information you've learned during your discussion and clinical assessment of the patient and through responses to the AIRQ® questions

Information on the Validation and Interpretation of the AIRQ®

1. The AIRQ® is a 10-item, equally weighted, yes/no composite asthma control questionnaire that includes 7 impairment and 3 risk items
2. The AIRQ® was validated against a standard of Asthma Control Test (ACT™) score (impairment) + prior-year, chart-documented exacerbations (risk) in 442 patients 12 years of age and older who were previously diagnosed with asthma
3. Multivariable logistic regression analyses were used to determine questions with the greatest validity in discriminating between patients of varying levels of control
4. A total of 10 questions were identified for inclusion in the AIRQ®
5. The AIRQ® performed well with respect to the ACT™ + exacerbations standard in identifying well-controlled vs not well-/very poorly controlled and well-/not well-controlled vs very poorly controlled asthma, with area under the receiver operating characteristic (ROC) curves of 0.94 and 0.93, respectively
6. The combination of selected AIRQ® items and cut points of control demonstrated a sensitivity of 0.90 to identify patients whose asthma was well-controlled (cut point of ≥ 2) and a specificity of 0.96 to determine patients whose asthma was very poorly controlled (cut point of ≥ 5)
7. For further information on the development and cross-sectional validation of the AIRQ®, please refer to Murphy KR, et al. *J Allergy Clin Immunol Pract.* 2020;8(7):2263-2274.e5 and Murphy KR, et al. *J Allergy Clin Immunol Pract.* 2021;9(1):603

AIRQ® (Asthma Impairment and Risk Questionnaire)



For use by health care providers with their patients 12 years and older who have been diagnosed with asthma. AIRQ® is intended to be part of an asthma clinic visit.

Please answer all of the questions below.

In the past 2 weeks, has coughing, wheezing, shortness of breath, or chest tightness:

- | | | |
|--|------------------------------------|-----------------------------------|
| 1. Bothered you during the day on <u>more than 4 days</u> ? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |
| 2. Woke you up from sleep <u>more than 1 time</u> ? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |
| 3. Limited the activities you want to do <u>every day</u> ? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |
| 4. Caused you to use your rescue inhaler or nebulizer <u>every day</u> ? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |



Primalene® MIST
(Amphastar
Pharmaceuticals)
or
Epinephrine



ProAir RespiClick®
(Teva Respiratory, LLC)
or
Albuterol sulfate



Proventil® HFA (Merck Sharp
& Dohme Corp., a subsidiary
of Merck & Co., Inc.)
or
Albuterol sulfate



Ventolin® HFA
(GlaxoSmithKline)
or
Albuterol sulfate



Xopenex HFA® (Sunovion
Pharmaceuticals Inc.)
or
Levalbuterol tartrate



Albuterol sulfate or Xopenex®
(Sunovion Pharmaceuticals Inc.)
or
Levalbuterol HCl

Please see all prescribing information for all products.

In the past 2 weeks:

- | | | |
|---|------------------------------------|-----------------------------------|
| 5. Did you have to limit your social activities (such as visiting with friends/relatives or playing with pets/children) because of your asthma? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |
| 6. Did coughing, wheezing, shortness of breath, or chest tightness limit your ability to exercise? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |
| 7. Did you feel that it was difficult to control your asthma? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |

In the past 12 months, has coughing, wheezing, shortness of breath, or chest tightness:

- | | | |
|---|------------------------------------|-----------------------------------|
| 8. Caused you to take steroid pills or shots, such as prednisone or Medrol®**? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |
| 9. Caused you to go to the emergency room or have unplanned visits to a health care provider? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |
| 10. Caused you to stay in the hospital overnight? | <input type="button" value="Yes"/> | <input type="button" value="No"/> |

Total YES Answers

What Does My AIRQ® Score Mean?

The AIRQ® is meant to help your health care providers talk with you about your asthma control. The AIRQ® does not diagnose asthma. Whatever your AIRQ® score (total YES answers), it is important for your health care team to discuss the number and answers to each of the questions with you. All patients with asthma, even those who may be well-controlled, can have an asthma attack. As asthma control worsens, the chance of an asthma attack increases.¹ Only your medical provider can decide how best to assess and treat your asthma.



*Medrol® (Pfizer, Inc.) or methylprednisolone

The trademarks depicted above are the property of their respective owners.

†Global Strategy for Asthma Management and Prevention: ©2022 Global Initiative for Asthma

©2023 AstraZeneca. All rights reserved. US-73060 Last Updated 2/23



SCAN here to
visit airqscore.com



AIRQ® is a registered trademark of AstraZeneca.

Printable Version of the AIRQ® in Spanish

AIRQ® (Cuestionario sobre la afectación y el riesgo en el asma)



Para uso de los proveedores de atención médica con sus pacientes mayores de 12 años que hayan sido diagnosticados de asma. El AIRQ® está diseñado para formar parte de una visita a una clínica de asma.

Por favor, responda todas las preguntas a continuación.

En las últimas dos semanas, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:

1. ¿Le molestaron en el transcurso del día durante **más de cuatro días**?
2. ¿Lo despertaron **más de una vez**?
3. ¿Limitaron las actividades que desea realizar **todos los días**?
4. ¿Hicieron que tuviera que usar su inhalador de rescate o nebulizador **todos los días**?



Primatene® MIST
(Amphastar
Pharmaceuticals)
o
epinefrina



Pro Air RespiClick® (Teva
Respiratory, LLC)
o
sulfato de albuterol



Proventil® HFA (Merck Sharp
& Dohme Corp., una filial de
Merck & Co., Inc.)
o
sulfato de albuterol



Ventolin® HFA
(GlaxoSmithKline)
o
sulfato de albuterol



Xopenex HFA® (Sunovion
Pharmaceuticals Inc.)
o
tartrato de levalbuterol



Sulfato de albuterol o Xopenex®
(Sunovion Pharmaceuticals
Inc.) o
levalbuterol HCl

Por favor, consulte la ficha técnica completa de todos los productos.

En las últimas dos semanas:

5. ¿Tuvo que limitar sus actividades sociales (como visitar a amigos/parientes o jugar con mascotas/niños) debido a su asma?
6. ¿La tos, la sibilancia, la dificultad para respirar o la presión en el pecho limitaron su capacidad de hacer ejercicio?
7. ¿Sintió que era difícil controlar su asma?

En los últimos 12 meses, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:


8. ¿Hicieron que tuviera que usar pastillas o inyecciones de corticosteroides, como prednisona o Medrol®?
9. ¿Hicieron que tuviera que ir a una sala de emergencias o consultas no planificadas con un proveedor de atención médica?
10. ¿Hicieron que tuviera que permanecer en el hospital durante la noche?

Total de respuestas "Sí"

¿Qué significa mi puntuación AIRQ®?

El AIRQ® tiene como objetivo ayudar a sus proveedores de atención médica a hablar con usted sobre el control de su asma. El AIRQ® no diagnostica el asma. Cualquiera que sea su puntuación de AIRQ® (total de respuestas **afirmativas**), es importante que su equipo de atención médica converse con usted acerca del número que obtenga y las respuestas a cada una de las preguntas. Todos los pacientes con asma, incluso aquellos que podrían estar bien controlados, pueden tener una crisis asmática. A medida que el control del asma empeora, la probabilidad de sufrir una crisis asmática aumenta.¹ Solamente su proveedor médico puede decidir la mejor manera de evaluar y tratar su asma.

Los proveedores de atención médica y los pacientes actúan juntos para controlar el asma



*Medrol® (Pfizer, Inc.) o metilprednisolona

Las marcas registradas que se muestran arriba son propiedad de sus respectivos dueños.

¹Estrategia mundial para el tratamiento y la prevención del asma: ©2021 Iniciativa mundial para el asma

©2023 AstraZeneca. Todos los derechos reservados.

AIRQ® es una marca registrada de AstraZeneca.

Epic Build Guide

English version

Administrative rights may be required to create the flowsheet.

1. The flowsheet build tool can be accessed by clicking the Epic Icon > Tools > Patient Care Tools > Doc Flowsheet Builder
2. Create a Flowsheet Template. For the Display Name, enter “Asthma Impairment and Risk Questionnaire (AIRQ®)”
3. Create 3 Documentation Flowsheet Groups in the Documentation Flowsheet Builder:

Flowsheet Group 1: “In the past 2 weeks, has coughing, wheezing, shortness of breath, or chest tightness:”

- In the Group/Row field:
 - Enter a record name or ID in the Create Group/Row field
- In the General form:
 - Enter the Display Name: **“In the past 2 weeks, has coughing, wheezing, shortness of breath, or chest tightness:”**
 - Select Flowsheet Group in the Row type field

Flowsheet Group 2: “In the past 2 weeks:”

- In the Group/Row field:
 - Enter a record name or ID in the Create Group/Row field
- In the General form:
 - Enter the Display Name: **“In the past 2 weeks:”**
 - Select Flowsheet Group in the Row type field

Flowsheet Group 3: “In the past 12 months, has coughing, wheezing, shortness of breath, or chest tightness:”

- In the Group/Row field:
 - Enter a record name or ID in the Create Group/Row field
- In the General form:
 - Enter the Display Name: **“In the past 12 months, has coughing, wheezing, shortness of breath, or chest tightness:”**
 - Select Flowsheet Group in the Row type field

English version (cont'd)

4. Create 10 Flowsheet Rows (to add to appropriate Flowsheet Group):

Flowsheet Group 1: “In the past 2 weeks, has coughing, wheezing, shortness of breath, or chest tightness:”

Row Display Name	Row Type	Value Type	Custom List	Value (Abbreviation)
1. Bothered you during the day on more than 4 days ?	Data	Custom List	Yes	1
			No	0
2. Woke you up from sleep more than 1 time ?	Data	Custom List	Yes	1
			No	0
3. Limited the activities you want to do every day ?	Data	Custom List	Yes	1
			No	0
4. Caused you to use your rescue inhaler or nebulizer every day ?	Data	Custom List	Yes	1
			No	0

Flowsheet Group 2: “In the past 2 weeks:”

Row Display Name	Row Type	Value Type	Custom List	Value (Abbreviation)
5. Did you have to limit your social activities (such as visiting with friends/relatives or playing with pets/children) because of your asthma?	Data	Custom List	Yes	1
			No	0
6. Did coughing, wheezing, shortness of breath, or chest tightness limit your ability to exercise?	Data	Custom List	Yes	1
			No	0
7. Did you feel that it was difficult to control your asthma?	Data	Custom List	Yes	1
			No	0

English version (cont'd)

Flowsheet Group 3: “In the past 12 months, has coughing, wheezing, shortness of breath, or chest tightness:”

Row Display Name	Row Type	Value Type	Custom List	Value (Abbreviation)
8. Caused you to take steroid pills or shots, such as prednisone or Medrol®*?	Data	Custom List	Yes	1
			No	0
9. Caused you to go to the emergency room or have unplanned visits to a health care provider?	Data	Custom List	Yes	1
			No	0
10. Caused you to stay in the hospital overnight?	Data	Custom List	Yes	1
			No	0

Note: Consider the Row Information field to add any additional information to populate in the Details window when entering information in a Flowsheet row.

For the row “Caused you to take steroid pills or shots, such as prednisone or Medrol®*?” add the following Row Information: *Medrol® (Pfizer, Inc.) or methylprednisolone.

5. Complete the last Flowsheet Row for the **AIRQ® Score**:


- In the General for view, enter the Display Name “AIRQ® Score”
- Enter **Custom Formula** in the Row type field with a **Numeric** Value Type
- In the Formula form, enter: **Custom Formula**: add all the previously created rows from the tables above [ID Row 1] + [ID Row 2] + ... + [ID Row 10]
- In the Row Information field, enter: “AIRQ® Score”

What Does My AIRQ® Score Mean?

“The AIRQ® is meant to help your health care providers talk with you about your asthma control. The AIRQ® does not diagnose asthma. Whatever your AIRQ® Score (total **YES** answers), it is important for your health care team to discuss the number and answers to each of the questions with you. All patients with asthma, even those who may be well-controlled, can have an asthma attack. As asthma control worsens, the chance of an asthma attack increases.¹ Only your medical provider can decide how best to assess and treat your asthma. Refer to the intended use document linked on this page to learn more about the AIRQ® and its intended use.”

- To add an image of the AIRQ rating scale below in the Row information field, select the Insert Linked Image button
- Select the location of the image file of the rating scale (<https://english.stick.airqimages.com/>) and click Open

The interpretation of the AIRQ® Score:



English version (cont'd)

6. Add the Flowsheet Rows from Step 4 to the Flowsheet Groups from Step 3
7. Add the Flowsheet Groups from Step 3 to the Flowsheet Template from Step 2
8. Add a link in the details Report to the Intended Use Document for the AIRQ® by opening the AIRQ® row record. Enter “Please review the intended use before completing the AIRQ®” and select the Insert Hyperlink button (or All Other Tools > Insert Hyperlink button)
9. In the Link address field, enter a link to the AIRQ® Intended Use Document (<http://us.english.intendeduse.airqassets.com/>). Confirm the website is accessible by end users. If the website is not accessible, work with the health system to whitelist the URL
10. In the Display Text field, enter “AIRQ® Intended Use Document” and click Accept
11. Once satisfactory testing has been completed, release for broader use
12. Consider adding the AIRQ® Flowsheet to a Visit Navigator Configuration (VCN) and Navigator Section for the AIRQ® Flowsheet
 - Duplicate an existing Navigator Configuration (MR_FLOWSHEET_DEFAULT) or other record. A duplicate can be created with a unique name and number
 - Enter the Flowsheet Template ID from the newly created AIRQ® Flowsheet in the Navigator Configuration Record
 - Duplicate an existing Navigator Configuration (SEC_FLOWSHEET_DEFAULT) or other record. A duplicate can be created with a unique name and number
 - Enter the caption and abbreviation (both AIRQ®), and change the Navigator Configuration Record
 - In the Management Console Workspace Setup, access the Navigator Template and add the AIRQ® Flowsheet to the desired Navigator
13. Consider creating a Synopsis report to trend the AIRQ® Score:
 - Create a flowsheet (FSH record) of “Synopsis” type
 - Select the Create tab and enter a unique name for the flowsheet (eg, AIRQ® Results) and click Accept. In the Choose Version (Contact Date) window, click Accept again
 - In the Flowsheet Editor, enter the desired data element(s) to use in the flowsheet
 - Add the following statement as a comment: “The graph above provides a convenient reference to past AIRQ® Scores. The graph depicts a patient’s level of asthma control over time, but the AIRQ® itself or change in AIRQ® over time cannot be used to diagnose asthma”
 - Create a Print Group Record (LPG type “Synopsis View Section”)
 - In the configuration screen, name the section header as desired (eg, AIRQ® Results)
 - Insert the flowsheet FSH ID for the AIRQ® Score and write down the print group LPG ID
 - Create an LRP report type “MR Synopsis View”
 - Set the Use Time Range to Yes
 - In the configuration screen, set the Default time window as desired and insert the print group LPG ID in the Synopsis View Sections and write down the LRP Report ID
 - Identify the necessary profiles (LPR) and insert the LRP Report ID in items 35000 (ID) and 35001 (Display Name)

Spanish version

Administrative rights may be required to create the flowsheet.

1. The flowsheet build tool can be accessed by clicking the Epic Icon > Tools > Patient Care Tools > Doc Flowsheet Builder
2. Create a Flowsheet Template. For the Display Name, enter “Asthma Impairment and Risk Questionnaire (AIRQ®) – Spanish version Cuestionario sobre la afectación y el riesgo en el asma (AIRQ®)”
3. Create 3 Documentation Flowsheet Groups in the Documentation Flowsheet Builder:

Flowsheet Group 1: “En las últimas dos semanas, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:”

- In the Group/Row field:
 - Enter a record name or ID in the Create Group/Row field
- In the General form:
 - Enter the Display Name: **“En las últimas dos semanas, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:”**
 - Select Flowsheet Group in the Row type field

Flowsheet Group 2: “En las últimas dos semanas:”

- In the Group/Row field:
 - Enter a record name or ID in the Create Group/Row field
- In the General form:
 - Enter the Display Name: **“En las últimas dos semanas:”**
 - Select Flowsheet Group in the Row type field

Flowsheet Group 3: “En los últimos 12 meses, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:”

- In the Group/Row field:
 - Enter a record name or ID in the Create Group/Row field
- In the General form:
 - Enter the Display Name: **“En los últimos 12 meses, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:”**
 - Select Flowsheet Group in the Row type field

Spanish version (cont'd)

4. Create 10 Flowsheet Rows (to add to appropriate Flowsheet Group):

Flowsheet Group 1: “En las últimas dos semanas, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:”

Row Display Name	Row Type	Value Type	Custom List	Value (Abbreviation)
1. ¿Le molestaron en el transcurso del día durante <u>más de cuatro días?</u>	Data	Custom List	Sí	1
			No	0
2. ¿Lo despertaron <u>más de una vez?</u>	Data	Custom List	Sí	1
			No	0
3. ¿Limitaron las actividades que desea realizar <u>todos los días?</u>	Data	Custom List	Sí	1
			No	0
4. ¿Hicieron que tuviera que usar su inhalador de rescate o nebulizador <u>todos los días?</u>	Data	Custom List	Sí	1
			No	0

Flowsheet Group 2: “En las últimas dos semanas:”

Row Display Name	Row Type	Value Type	Custom List	Value (Abbreviation)
5. ¿Tuvo que limitar sus actividades sociales (como visitar a amigos/parientes o jugar con mascotas/niños) debido a su asma?	Data	Custom List	Sí	1
			No	0
6. ¿La tos, la sibilancia, la dificultad para respirar o la presión en el pecho limitaron su capacidad de hacer ejercicio?	Data	Custom List	Sí	1
			No	0
7. ¿Sintió que era difícil controlar su asma?	Data	Custom List	Sí	1
			No	0

Spanish version (cont'd)

Flowsheet Group 3: “En los últimos 12 meses, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:”

Row Display Name	Row Type	Value Type	Custom List	Value (Abbreviation)
8. ¿Hicieron que tuviera que usar pastillas o inyecciones de corticosteroides, como prednisona o Medrol®*?	Data	Custom List	Sí	1
			No	0
9. ¿Hicieron que tuviera que ir a una sala de emergencias o consultas no planificadas con un proveedor de atención médica?	Data	Custom List	Sí	1
			No	0
10. ¿Hicieron que tuviera que permanecer en el hospital durante la noche?	Data	Custom List	Sí	1
			No	0

Note: Consider the Row Information field to add any additional information to populate in the Details window when entering information in a Flowsheet row.

For the row “¿Hicieron que tuviera que usar pastillas o inyecciones de corticosteroides, como prednisona o Medrol®*?” add the following Row Information: *Medrol® (Pfizer, Inc.) o metilprednisolona.

5. Complete the last Flowsheet Row for the **Total de Respuestas “Sí”**:

- In the General for view, enter the Display Name “Total de Respuestas “Sí””
- Enter **Custom Formula** in the Row type field with a **Numeric** Value Type
- In the Formula form, enter: **Custom Formula**: add all the previously created rows from the tables above [ID Row 1] + [ID Row 2] + ... + [ID Row 10]
- In the Row information field, enter: “Total de Respuestas “Sí””

¿Qué significa mi puntuación AIRQ®?

“El AIRQ® tiene como objetivo ayudar a sus proveedores de atención médica a hablar con usted sobre el control de su asma. El AIRQ® no diagnostica el asma. Cualquiera que sea su puntuación de AIRQ® (total de respuestas **AFIRMATIVAS**), es importante que su equipo de atención médica converse con usted acerca del número que obtenga y las respuestas a cada una de las preguntas. Todos los pacientes con asma, incluso aquellos que podrían estar bien controlados, pueden tener una crisis asmática. A medida que el control del asma empeora, la probabilidad de sufrir una crisis asmática aumenta.¹ Solamente su proveedor médico puede decidir la mejor manera de evaluar y tratar su asma. Consulte el documento de uso previsto vinculado en esta página para obtener más información sobre el AIRQ® y su uso previsto.”

- To add an image of the AIRQ rating scale below in the Row information field, select the Insert Linked Image button
- Select the location of the image file of the rating scale (<https://spanish.stick.airqimages.com/>) and click Open

The interpretation of the AIRQ® Score:



14 *Medrol® (Pfizer, Inc.) o metilprednisolona
 Las marcas registradas que se muestran arriba son propiedad de sus respectivos dueños.
¹Estrategia mundial para el tratamiento y la prevención del asma: ©2023 Iniciativa mundial para el asma

Spanish version (cont'd)

6. Add the Flowsheet Rows from Step 4 to the Flowsheet Groups from Step 3
7. Add the Flowsheet Groups from Step 3 to the Flowsheet Template from Step 2
8. Add a link in the details Report to the Intended Use Document for the AIRQ® by opening the AIRQ® row record. Enter “Revise el uso previsto antes de completar el AIRQ®” and select the Insert Hyperlink button (or All Other Tools > Insert Hyperlink button)
9. In the Link address field, enter a link to the AIRQ® Intended Use Document (<http://us.spanish.intendeduse.airqassets.com>). Confirm the website is accessible by end users. If the website is not accessible, work with the health system to whitelist the URL
10. In the Display Text field, enter “AIRQ® Intended Use Document” and click Accept
11. Once satisfactory testing has been completed, release for broader use
12. Consider adding the AIRQ® Flowsheet to a Visit Navigator Configuration (VCN) and Navigator Section for the AIRQ® Flowsheet
 - Duplicate an existing Navigator configuration (MR_FLOWSHEET_DEFAULT) or other record. A duplicate can be created with a unique name and number
 - Enter the Flowsheet Template ID from the newly created AIRQ® Flowsheet in the Navigator Configuration Record
 - Duplicate an existing Navigator configuration (SEC_FLOWSHEET_DEFAULT) or other record. A duplicate can be created with a unique name and number
 - Enter the caption and abbreviation (both AIRQ®), and change the Navigator Configuration Record
 - In the Management Console Workspace Setup, access the Navigator Template and add the AIRQ® Flowsheet to the desired Navigator
13. Consider creating a Synopsis report to trend the AIRQ® Score:
 - Create a flowsheet (FSH record) type “Synopsis”
 - Select the Create tab and enter a unique name for the flowsheet (eg, AIRQ® Results) and click Accept. In the Choose Version (Contact Date) window, click Accept again
 - In the Flowsheet Editor, enter the desired data element(s) to use in the flowsheet
 - Add the following statement as a comment: “The graph above provides a convenient reference to past AIRQ® Scores. The graph depicts a patient’s level of asthma control over time, but the AIRQ® itself or change in AIRQ® over time cannot be used to diagnose asthma”
 - Create a Print Group Record (LPG type “Synopsis View Section”)
 - In the configuration screen, name the section header as desired (eg, AIRQ® Results)
 - Insert the flowsheet FSH ID for the AIRQ® Score and write down the print group LPG ID
 - Create an LRP report type “MR Synopsis View”
 - Set the Use Time Range to Yes
 - In the configuration screen, set the Default time window as desired and insert the print group LPG ID in the Synopsis View Sections and write down the LRP Report ID
 - Identify the necessary profiles (LPR) and insert the LRP Report ID in items 35000 (ID) and 35001 (Display Name)

Implementing the Follow-Up AIRQ®

It is recommended that patients complete the AIRQ® once every 12 months. If you wish for patients to complete the AIRQ® for HCP encounters in the interim, patients should complete the Follow-Up AIRQ®.

The Follow-Up AIRQ® is almost identical to the AIRQ®; the sole exception is the stem language appearing immediately before question 8:

AIRQ®	Follow-Up AIRQ®
In the <u>past 12 months</u> , has coughing, wheezing...	In the <u>past 3 months</u> , has coughing, wheezing...

If you wish to administer the Follow-Up AIRQ® in your practice, you will need to implement a second version of the AIRQ® in your system, observing the sole difference in language as noted above.

To execute, update the label set in Steps 3 and 4 of the Flowsheet build guide to the following (the sole difference in language is highlighted for your illustration):

- English version:
"In the past 3 months, has coughing, wheezing, shortness of breath, or chest tightness."
- Spanish version:
"En los últimos 3 meses, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho."

It would be up to your staff to ensure that the patient is directed to the appropriate version of the AIRQ® and whether they need to complete the AIRQ® for their annual visit or the Follow-Up AIRQ® for an interim encounter.

Certification

This is to certify that RWS Life Sciences, Inc. has performed the following procedures on the **AIRQ (Asthma Impairment and Risk Questionnaire)**[RWS Life Sciences Job #:221-G3463A-LMNLV]:

Source File Name: AIRQ (Asthma Impairment and Risk Questionnaire)_cv1_Orig_WS_Paper_English-US_15Sep2022

Target File Name: AIRQ (Asthma Impairment and Risk Questionnaire)_cv1_Trans_WS_Paper_Spanish-US_29Dec2022

- Desktop publishing of previously validated translation
- Proofreading of previously validated translation

These documents were prepared by a translator who is fully bilingual in both Spanish for the United States and English. All procedures were performed in accordance with current industry standards and FDA guidance.

Authorized Signature:



Elizabeth McCullough
Director of Linguistic Validation Operations

Date of Production: 29 December 2022